argenex SE $ARGX Stock: CenterBook Partners LP Grows Stake

CenterBook Partners LP increased its stake in shares of argenex SE (NASDAQ:ARGX) by 2,473.9% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 12,226 shares of the company’s stock after acquiring an additional 11,751 shares during the period. CenterBook Partners LP’s holdings in argenex were worth $11,724,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in ARGX. Janus Henderson Group PLC boosted its position in argenex by 3.4% during the first quarter. Janus Henderson Group PLC now owns 2,541,732 shares of the company’s stock worth $1,847,592,000 after purchasing an additional 83,568 shares during the period. Jennison Associates LLC raised its position in shares of argenex by 3.4% in the first quarter. Jennison Associates LLC now owns 237,468 shares of the company’s stock valued at $173,411,000 after purchasing an additional 7,707 shares during the period. Allspring Global Investments Holdings LLC raised its position in shares of argenex by 1.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 175,311 shares of the company’s stock valued at $130,277,000 after purchasing an additional 2,579 shares during the period. First Trust Advisors LP raised its position in shares of argenex by 98.9% in the first quarter. First Trust Advisors LP now owns 107,195 shares of the company’s stock valued at $78,279,000 after purchasing an additional 53,293 shares during the period. Finally, Eagle Health Investments LP raised its position in shares of argenex by 21.7% in the first quarter. Eagle Health Investments LP now owns 76,336 shares of the company’s stock valued at $55,744,000 after purchasing an additional 13,606 shares during the period. 60.32% of the stock is owned by institutional investors.

argenex Stock Up 3.6%

Shares of ARGX stock traded up $32.44 during trading hours on Friday, reaching $927.21. 378,409 shares of the company’s stock were exchanged, compared to its average volume of 506,127. argenex SE has a fifty-two week low of $661.85 and a fifty-two week high of $1,072.75. The stock has a market capitalization of $58.31 billion, a P/E ratio of 32.35, a P/E/G ratio of 0.81 and a beta of 0.48. The business has a fifty day moving average price of $930.66 and a 200-day moving average price of $857.30.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Friday, October 23rd. The company reported $7.80 earnings per share for the quarter, beating the consensus estimate of $7.44 by $0.36. argenex had a return on equity of 47.70% and a net margin of 31.66%. The company had revenue of $1.75 billion during the quarter. As a group, research analysts expect that argenex SE will post 28.41 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on ARGX shares. HC Wainwright upped their price objective on shares of argenex from $940.00 to $1,202.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. DZ Bank reiterated a “buy” rating on shares of argenex in a report on Friday, October 9th. Wall Street Zen lowered shares of argenex from a “buy” rating to a “hold” rating in a research report on Sunday, October 25th. Weiss Ratings reissued a “hold (c)” rating on shares of argenex in a research report on Wednesday, October 21st. Finally, Sanford C. Bernstein restated a “buy” rating on shares of argenex in a report on Thursday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, argenex presently has a consensus rating of “Moderate Buy” and an average price target of $1,158.76.

argenex Company Profile

argenx SE is a global immunology company focused on developing medicines for autoimmune diseases. Founded in 2008 and headquartered in the Netherlands, the company uses antibody engineering and other research approaches to identify and develop treatments for conditions with significant unmet medical needs.

Its lead medicine is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo. These products target the neonatal Fc receptor (FcRn) and are approved in the United States for certain patients with generalized myasthenia gravis; Vyvgart Hytrulo is also approved for chronic inflammatory demyelinating polyneuropathy.